Gastroenterology and Liver

Autoimmune Liver Diseases

Autoimmune liver diseases, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are chronic conditions characterized by immune-mediated liver damage. Early diagnosis and prompt treatment are essential to prevent disease progression and liver failure. These conditions often require a multidisciplinary approach involving hepatologists, immunologists, and other specialists to optimize patient care.

Autoimmune hepatitis (AIH) is managed with immunosuppressive therapies, such as corticosteroids and azathioprine, to reduce liver inflammation and achieve remission. Regular monitoring and adjustments in therapy are necessary to maintain disease control and minimize side effects. In refractory cases, second-line agents, such as mycophenolate mofetil and calcineurin inhibitors, may be considered. For primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) is the mainstay of treatment, improving liver function and delaying disease progression. Obeticholic acid, a farnesoid X receptor agonist, is used in patients who do not respond adequately to UDCA.

Primary sclerosing cholangitis (PSC) poses significant therapeutic challenges due to the lack of effective medical treatments. Management focuses on symptom relief, prevention of complications, and monitoring for disease progression and malignancies. Liver transplantation remains the definitive treatment for patients with end-stage autoimmune liver disease or those with complications such as cholangiocarcinoma. Ongoing research aims to identify novel therapeutic targets and biomarkers to improve the management and outcomes of autoimmune liver diseases.